All News

Found 5,910 articles

• Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

  11/2/2023

  Cellectis announced today that preliminary results of the Phase I NATHALI-01 clinical trial evaluating UCART20x22 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL) and updated results of the Phase I BALLI-01 clinical trial evaluating UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, (r/r B-ALL) will be presented at the American Society of Hematology 65th Annual Meeting (ASH 2023).

• Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/2/2023

  Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

• Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

  11/2/2023

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended September 30, 2023, and provided a business update.  

• Stupid Strong Charitable Foundation Pledges $450,000 Grant to Advance Gastric Cancer Family Study

  11/1/2023

  The Stupid Strong Charitable Foundation is proud to announce a significant commitment of $450,000 in grant funding over four years to support a groundbreaking research project at The University of Texas MD Anderson Cancer Center.

• The Leukemia & Lymphoma Society Awards $65 Million in New Funding for Blood Cancer Research

  11/1/2023

  The Leukemia & Lymphoma Society, the largest private funder of blood cancer research, announced $65 million in new grants to 78 research teams across seven countries.

• Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

  11/1/2023

  Antengene Corporation Limited announced that it has presented results from five programs by poster presentation, including two clinical programs on the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101.

• BostonGene to Present Research with Leading Cancer Centers at Society for Immunotherapy of Cancer’s 2023 Annual Meeting

  11/1/2023

  BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA.

• Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

  10/31/2023

  Syncromune®, Inc. proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

• Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

  10/31/2023

  Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA.

• Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome

  10/31/2023

  Nouscom today announced that promising interim data from a Phase 1b trial evaluating NOUS-209 in Lynch Syndrome (LS) carriers was published in a Late-breaking Abstract and will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA.

• Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

  10/30/2023

  Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) released highlights from a clinical update event held today, October 30, 2023, in conjunction with the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held in Estoril, Portugal (the “ESH 2023 Conference”).

• Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

  10/27/2023

  Lunit (KRX:328130.KQ) today announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck's (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types.

• Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694

  10/26/2023

  Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics' ZEN-3694 program.

• Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

  10/26/2023

  Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

• REHEVA BIOSCIENCES SUCCESSFULLY COMPLETES RH324 PHASE I CLINICAL TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

  10/25/2023

  ReHeva Biosciences, a pioneering biopharmaceutical startup with the mission to help people live longer and healthier with cancer through naturally derived complex drugs, proudly announces the successful completion of its Phase I Safety Trial for its novel drug, RH324.

• Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication

  10/25/2023

  Panbela Therapeutics, Inc today announced that an abstract about SBP-101 and CPP-1X (also known as DFMO or Eflornithine) research in multiple myeloma (cell lines), has been accepted for an online publication on the American Society of Hematology (ASH) meeting site in the November supplemental issue of the journal Blood.

• TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

  10/25/2023

  TriSalus Life Sciences® Inc. announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer 38th Annual Meeting being held November 1-5, 2023, in San Diego, California.

• BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

  10/25/2023

  BriaCell Therapeutics Corp. is pleased to announce the formation of its medical advisory board and the appointment of three distinguished breast cancer key opinion leaders Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the addition of Charles Sidman, PhD, MBA, to its scientific advisory board.

• Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

  10/25/2023

  Carisma Therapeutics Inc. today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California.

• Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

  10/24/2023

  Bio-Path Holdings, Inc. announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia.